Case Comprehensive Cancer Center

September 30 marks Rare Cancer Day each year. But this year, the end of September was made even more meaningful to Case CCC thanks to a gift from the Jed Ian Taxel Foundation for Rare Cancer Research (JEDI). The $5 million launches CURE: The Rare Cancer Initiative at Case CCC. The gift is in…

It's Breast Cancer Awareness Month and G. Thomas Budd, MD, member of Case CCC's Immune Oncology Program, is getting noticed as the PI for his contribution to the vaccine created to find and attack the protein alpha-lactalbumin, an indicator of triple-negative breast cancer if found in women who are…

As National Rare Cancer Day nears (Sept. 30), Jed Ian Taxel Foundation for Rare Cancer Research announces major gift to spur cross-country collaboration Less than six months after Jed Ian Taxel’s diagnosis with a rare metastatic cancer, he learned his treatment was ineffective. Weeks before his…

Awarded five-year, $3.05 million grant from National Institutes of Health, National Cancer Institute With a new five-year, $3.05 million grant from the National Institutes of Health and National Cancer Institute, researchers at the Case Comprehensive Cancer Center and University Hospitals (UH)…

A new $2 million grant from the Mt. Sinai Health Foundation has established the Mt. Sinai Fellows in Therapeutic Discovery, an effort to support the recruitment of exceptional mid-career MD/PhD researchers to participate in an interdisciplinary collaborative that includes CWRU's hospital…

Fellows program to attract leading researchers to collaborate with university and hospital colleagues to develop promising solutions—and get them to patients After helping to launch the careers of 30 medical school researchers, the Mt. Sinai Health Foundation is partnering again with Case Western…

Kaixiang Cao, PhD, a member of Case CCC's Cancer Genomics & Epigenomics program, is challenging the current paradigms for using the LSD1 (lysine-specific histone demethylase 1A) protein to slow cancer growth. He and his team posit that the entire LSD1 protein can be completely degraded rather…

Erika Trapl, PhD, Case CCC's Associate Director for Community Outreach and Engagement, Charles Modlin, MD, MBA, Director of the MetroHealth Minority Men's Health Institute, and Waverly Willis, owner/operator of two Urban Kutz barbershops and member of Case CCC's Community Advisory Board, discussed…

Joel Saltzman, MD, a member of Case CCC's Developmental Therapeutic Program and a clinician in the Department of Hematology and Oncology at Cleveland Clinic Taussig Cancer Institute, has been named a Fellow of the American Society of Clinical Oncology (FASCO). An ASCO member is recognized as a…

Case Western Reserve biochemists focus on degrading key cancer-driving protein; represents major shift in research Case Western Reserve University biochemical researchers have identified a new function of a key protein that leads to cancer—a finding they believe could lead to more effective…